The Latest Breaking News from SVB Securities

Eli Lilly is the IBD Stock Of The Day as investors watch the company's obesity and Alzheimer's drugs, which could help shares skyrocket.

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Merck is now in advanced talks to buy Seagen for roughly $40 billion, according to reports that sent SGEN stock higher Thursday.

Today Blueprint Medicines Corp (NASDAQ:BPMC) announced strategic financing agreements with Sixth Street and Royalty Pharma Plc (NASDAQ:RPRX) for up to $1.25 billion, including $575 million upfront upon deal closure. SVB Securities thinks the terms of the deals are fairly valued on the Sixth Street portion and favorable for Blueprint Medicines on the Royalty Pharma portion. "In addition,…

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted an option for a period of 30 days to purchase an additional 15% of common shares at the public offering price. Jefferies, J.P. Morgan, SVB Securities, and Stifel are acting as joint…

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Caribou Biosciences Inc (NASDAQ:CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).  Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6…

Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases.  According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

The FDA accepted Travere Therapeutics' application for a kidney disease treatment on Monday, leading TVTX stock to surge higher.